Old arthritis drug tested against rare tumor syndrome – but trial stalls
NCT ID NCT05605587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested leflunomide, a drug used for rheumatoid arthritis, in 3 adults with MEN1 syndrome—a genetic condition that raises the risk of multiple tumors. The goal was to see if 6 months of daily leflunomide could shrink or stabilize tumors. However, the trial was terminated early, so we have very little information on whether it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Leflunomide (20 mg daily for 6 months)
- What this could lead to
- If it works, leflunomide could offer a new way to slow or shrink tumors in people with MEN1 syndrome.
- What could go wrong
- This was a very small, early trial that ended early, so we don't have enough data to know if it works. Leflunomide can also cause side effects like liver problems or low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEN1 GENE MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Unispital Basel
Basel, 4053, Switzerland